IDEMIA
23.2.2018 16:59:12 CET | Business Wire | Press release
IDEMIA, the global leader in Augmented Identity for an increasingly digital world, announces today that it has implemented facial recognition technology on EasyOpen, a solution previously developed with its partner Omoove, a wholly-owned Octo Telematics company, Europe’s leading Shared Mobility technology provider. The digital enrolment process combined with facial recognition technology will securely enroll and authenticate the driver before EasyOpen automatically opens the car.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180223005506/en/
You will never rent a car the same way thanks to EasyOpen solution that combines IDEMIA’s expertise in secure service enablement and Omoove’s experience in Shared Mobility platforms and on-board technology.
The first version of the solution was launched last year and allows drivers, who have already registered on the application, to use their smartphones as a key to open their cars in a secure way.
This year, both companies have just announced the introduction of a new process for the digital enrollment of the driver combined with facial recognition technology, which will be implemented into EasyOpen solution.
This solution uses the smartphone to create the identity of the driver by registering ID documents in a fast and user-friendly way, while afterwards granting access to the car through a selfie thanks to IDEMIA’s facial recognition solution.
According to a study run by Frost & Sullivan (www.frost.com ), car sharing users number should increase by 16,4% CAGR within 2025 : private car usage will then decrease and car rental agencies will need high performing technologies to secure shared cars. In that context, IDEMIA and Omoove strengthen their position on this promising market with the extremely simple, intuitive and fast EasyOpen solution. A demonstration of EasyOpen will take place at the Mobile World Congress 2018: end-to-end customer journey from registration on car rental application to opening of the car thanks to a selfie will be presented on this occasion on a Maserati Levante .
Yves Portalier, Executive Vice President of the Connected Objects business at IDEMIA declared: “After implementing a keyless solution last year, IDEMIA is now adding facial recognition technology to the end-user experience thus providing fast and secure registration and trusted online authentication. By combining increased security with additional convenience, we’re making the user experience even more simple in this promising car sharing market. ”
Giuseppe Zuco, CEO at Omoove and Octo Telematics co-founder, added: “We are pleased to participate once again with IDEMIA at the MWC; together with strengthening our partnership, we continue to share our expertise in automotive solutions and IoT applications. We look forward to showing a new mobility experience, through advanced biometrics and secure digital identity management. The keyless connected car will unveil a new era of shared Mobility, by simplifying the driver journey and allowing operators to offer a simple and reliable solution”.
No keys, no card, you only need a smartphone to open the car and
start the journey!
Discover the service at the Mobile World
Congress on IDEMIA ’s booth, Hall 6 Booth #6H30
Visit our virtual press room: http://mwc.vporoom.com/IDEMIA
About IDEMIA
OT-Morpho is now IDEMIA, the global leader in Augmented Identity for an increasingly digital world, with the ambition to empower citizens and consumers alike to interact, pay, connect, travel and vote in ways that are now possible in a connected environment.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable transactions for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
OT (Oberthur Technologies) and Safran Identity & Security (Morpho) have joined forces to form IDEMIA. With close to $3 billion in revenues and 14,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
About Octo Telematics
Octo is the number 1 global provider of telematics and data analytics
solutions for the auto insurance industry. Founded in 2002, Octo is one
of the pioneers of the insurance telematics industry. Today, Octo is the
largest and most experienced insurance telematics company in the world,
transforming auto insurance through behavioral, contextual and driving
analytics for more than 100 insurance partners.
Octo has more than
5.4 million connected users and the largest global database of
telematics data, with over 186 billion miles of driving data collected
and 438,000 crashes and insurance events analyzed (as of 31 December
2017).
Octo applies proprietary algorithms to this market-leading
database to deliver powerful new insights into driver risk, informing
solutions that benefit both auto insurance companies and policyholders.
The
company is headquartered in London, with offices in Boston, Rome,
Stuttgart, Madrid, and Sao Paulo.
For more information, visit www.octotelematics.com
About Omoove
Omoove is the European leader in providing innovative technological
solutions in the Mobility market, offering end-to-end Shared Mobility,
Fleet Management and Insurance Telematics technologies and solutions for
Vehicle Sharing Operators and Car Rental Companies.
Omoove operates
more than 10 car sharing services in 15 cities with about 200.000
connected vehicles and scooters, 900.000 registered users and more than
400.000 rentals per month (as of 31 December 2017). Founded in 2001,
Omoove is wholly-owned by Octo Telematics, the largest and most
experienced insurance telematics company in the world for number of
registered users and managed vehicles. Omoove is headquartered in Rome
with local offices in France, Spain, UK, Germany and the United States.
For more information, visit www.omoove.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180223005506/en/
Contact:
Press contacts
IDEMIA: Havas PR agency
Idemia@havas.com
+
33 6 63 73 30 30
or
OCTO TELEMATICS - OMOOVE
Adriana
Zambon
+39 339 3995640
press.it@octotelematics.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom